Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State
Akhatova A. Azizan A. Atageldiyeva K. Ashimkhanova A. Marat A. Iztleuov Y. Suleimenova A. Shamkeeva S. Aimagambetova G.
November 2022MDPI
Vaccines
2022#10Issue 11
Immunization is the most successful method in preventing and controlling infectious diseases, which has helped saving millions of lives worldwide. The discovery of the human papillo-mavirus (HPV) infection being associated with a variety of benign conditions and cancers has driven the development of prophylactic HPV vaccines. Currently, four HPV vaccines are available on the pharmaceutical market: Cervarix, Gardasil, Gardasil-9, and the recently developed Cecolin. Multiple studies have proven the HPV vaccines’ safety and efficacy in preventing HPV-related diseases. Since 2006, when the first HPV vaccine was approved, more than 100 World Health Organization member countries reported the implementation of HPV immunization. However, HPV vaccination dread, concerns about its safety, and associated adverse outcomes have a significant impact on the HPV vaccine implementation campaigns all over the world. Many developed countries have successfully implemented HPV immunization and achieved tremendous progress in preventing HPV-related conditions. However, there are still many countries worldwide which have not created, or have not yet implemented, HPV vaccination campaigns, or have failed due to deficient realization plans associated with establishing successful HPV vaccination programs. Lack of proper HPV information campaigns, negative media reflection, and numerous myths and fake information have led to HPV vaccine rejection in many states. Thus, context-specific health educational interventions on HPV vaccination safety, effectiveness, and benefits are important to increase the vaccines’ acceptance for efficacious prevention of HPV-associated conditions.
Cecolin , Cervarix , cervical cancer prevention , Gardasil , Gardasil-9 , HPV , HPV vaccination , HPV vaccination acceptance , prophylactic HPV vaccine
Text of the article Перейти на текст статьи
School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Department of Basic Sciences, College of Osteopathic Medicine, Touro University, Henderson, 89014, NV, United States
Department of Medicine, School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
Clinical Academic Department of Internal Medicine, CF University Medical Center, Astana, 10000, Kazakhstan
Department of Obstetrics and Gynecology #1, NJSC “Astana Medical University”, Astana, 010000, Kazakhstan
Medical Center, Marat Ospanov West-Kazakhstan Medical University, Aktobe, 030000, Kazakhstan
Kazakh Institute of Oncology and Radiology, Almaty, 050000, Kazakhstan
Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics, Leipzig University Hospital, Leipzig, 04103, Germany
Department of Biomedical Sciences, School of Medicine, Nazarbayev University, Astana, 010000, Kazakhstan
School of Medicine
Department of Basic Sciences
Department of Medicine
Clinical Academic Department of Internal Medicine
Department of Obstetrics and Gynecology #1
Medical Center
Kazakh Institute of Oncology and Radiology
Institute of Laboratory Medicine
Department of Biomedical Sciences
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026